Mr Thomas Friedmann > Dechert LLP > Boston, United States > Lawyer Profile

Dechert LLP continues to be rated for its expertise in life sciences and permanent capital vehicles; it is a dominant force in issuances by business development companies (BDCs). It recently advised Blackstone Private Credit Fund on its $500m private placement of 2.700% senior secured notes due 2025 and $650m private placement of 4.000% senior secured notes due 2029. Jay Alicandri is a major force in DCM offerings in the permanent capital and private credit segments. Boston partner Thomas Friedmann is co-head of corporate finance and capital markets and co-head of permanent capital, frequently advising on capital markets offerings by BDCs.

Also noted for its capabilities in life sciences-related work, Dechert LLP‘s strength in offerings by financial institutions, including permanent capital vehicles, provides a platform for a steady pipeline of debt offering engagements. New York partner Jay Alicandri is active in high-yield debt offerings in the permanent capital and private credit sphere. Boston’s Thomas Friedmann and Philadelphia partner Ian Hartman are also key partners within the national practice.

Dechert LLP’s capital markets practice remains closely associated with life sciences and permanent capital vehicles, including business development companies. It is also noted for cross-border offerings, including those from Latin America. Thomas Friedmann, Boston managing partner and co-chair of the capital markets group, is noted for permanent capital vehicle transactions. New York partner David S Rosenthal co-heads the capital markets group and has a long track record in life sciences transactions.

Dechert LLP has an established record in cross-border offerings, particularly those involving Latin America. It is also active in cross-border offerings for permanent capital vehicles and business development companies. Recently, it advised Blackstone Private Credit Fund, a closed-end management investment company and business development company, on its inaugural euro-dominated offering of €500m of 1.750% Notes due 2026. Boston’s Thomas Friedmann and New York partner David S Rosenthal, a life sciences specialist, co-chair the capital markets practice. Howard Kleinman departed for McDermott Will & Emery LLP in July 2023.